



2017 Alliance Fall Group Meeting
 Loews Chicago O'Hare Hotel – Rosemont, IL
 November 4, 2017
 7:00 a.m – 12:00 p.m.
 [Room]

2017 Fall Alliance Group Meeting Agenda
 Leukemia/Leukemia Correlative Sciences Agenda

Chair(s): Richard M. Stone, MD; John C. Byrd, MD
 Vice-Chairs: Guido Marcucci, MD (LC); Tom Shea, MD (LC), Wendy Stock, MD, PhD (LC/LCS)

7:00 – 7:10	Introduction	Richard Stone, MD/John Byrd, MD
7:10 – 7:20	Update: Leukemia Correlative Sciences	John Byrd, MD
7:20 – 7:30	Statistics and Data Management	Sumithra Mandrekar, PhD, et al
7:30 – 8:00	Using innovative techniques to determine disease persistence and resistance in acute leukemias	Jerome Radich, MD, PhD
8:00 – 8:15	ASH abstract : Midostaurin therapy in mutant FLT3 AML	Richard Larson, MD
8:15 – 8:30	ASH abstract: Cumulative Incidence of Relapse in C10603	Richard Stone, MD
	Trial Updates	
8:30 – 8:45 (Active)	Chemo +/- blinatumomab in middle aged adults with pre-B-ALL: (Study#:E1910; Study Chairs:M.Litzow,MD;M.Wieduwilt,MD (A))	M.Wieduwilt, MD
8:45-9:00 (In Develop)	PH+ALL working group concepts	K. Jamieson, MD
9:00 – 9:15 (Active)	Aya chem +/- inotuzumab in younger adults with B cell ALL (Study#:A041501; Study Chair: D.DeAngelo,MD/PhD)	D.DeAngelo, MD/PhD
9:15 – 9:30 (In Develop)	Dual Ab rx of relapsed Ph-ALL and use in older adults (Study#A041703; Study Chair:M.Wieduwilt, MD)	M. Wieduwilt, MD
Notation Only (Recently Closed)	FCR 'vs' ibrutinib in younger CLL (Study#E1912; Study Chairs:T Shanafelt, MD; J.Barrientos, MD(A))	J. Barrientos, MD (notation only)
(Recently Closed)	Ibrutinib 'vs' ibrutinib/rituximab in older adults with untreated CLL (Study#:A041202; Study Chair:J.Woyach, MD)	J. Woyach, MD (notation only)
9:30 – 9:35 (In Develop)	Early intervention in CLL: I or IVO 'vs' delayed IVO (Study#:S1718; Study Chair:D.Stephens, MD)	J. Byrd, MD
9:35 – 9:45 (In Develop)	Younger CLL: Targeted therapy 'vs' I/O (Study#EA9161; Study Chairs:T.Shanafelt,MD)	J. Byrd, MD
9:45 – 10:00 (In Develop)	I/O 'vs' ibrutinib/obino/venet in older CLL (Study#:A041702;Study Chair:J.Woyach,MD)	J.Woyach,MD

10:15 – 10:25 (Almost active)	7+3 + novel agent in elderly AML + older unfit SWOG trial (Study#S1612;Study Chair::G.Uy, MD;L.Michaelis, MD)	G.Uy, MD
10:25 – 10:45 (In Develop)	7+3+/- E selectin inhibition (Study#A041701;Study Chair:G.Uy, MD)	G. Uy MD
10:45 – 11:15 (Overview)	Young adults in AML: NCI, precision medicine, and cassettes	R. Little, MD
11:15-11:45 (In Develop)	Where are we going in younger adults with AML?	Group
11:45 – Noon (In Develop)	Update on MDS trials	T.Odenike, MD